Convergence Pharmaceuticals announces start of Phase II study for CNV1014802 Convergence Pharmaceuticals announces start of Phase II study for CNV1014802

Convergence Pharmaceuticals today announced that the Phase II proof of concept study with CNV1014802 for treating pain associated with lumbosacral radiculopathy (LSR) has started.
19 July 2011

Mental health problems after miscarriage continue after healthy birth Mental health problems after miscarriage continue after healthy birth

Women who experience depression and anxiety after a miscarriage continue to experience these symptoms even if they subsequently go on to have a healthy child.
03 March 2011

AstraZeneca and Pfizer Join Cancer Research UK’s Stratified Medicine Programme AstraZeneca and Pfizer Join Cancer Research UK’s Stratified Medicine Programme

CANCER RESEARCH UK will be supported by AstraZeneca and Pfizer in a multimillion pound initiative to examine how genetic tests to improve cancer diagnosis can be best rolled out across the NHS.Cancer Research UK’s pioneering “Stratified Medicine Programme”* will also promote research into new targeted treatments by building a database of genetic information about tumours, treatments and survival rates that will enable researchers to design more effective cancer treatments in future.
01 February 2011

GSK and Prosensa announce start of Phase III study of investigational Duchenne Muscular Dystrophy medication GSK and Prosensa announce start of Phase III study of investigational Duchenne Muscular Dystrophy medication

GlaxoSmithKline (GSK) and Prosensa today announced that the first patient has commenced treatment in the Phase III study investigating GSK2402968, in ambulant boys with Duchenne Muscular Dystrophy (DMD), who have a dystrophin gene mutation amenable to an exon 51 skip
19 January 2011

Cancer Research UK and AstraZeneca Collaborate to Trial Combinations of New Cancer Drugs Cancer Research UK and AstraZeneca Collaborate to Trial Combinations of New Cancer Drugs

CANCER RESEARCH UK’s drug development office (DDO) has signed a Strategic Combinations Alliance with AstraZeneca to take combinations of experimental cancer drugs into early phase clinical trials.The move will increase patient access to trials of potential new cancer treatments that combine molecularly targeted experimental drugs developed and owned by AstraZeneca. The trials will also test these combinations alongside conventional chemotherapy radiotherapy and other novel agents.
14 January 2011

First Effective Non-Opioid Treatment in Two Decades Could be Available Within Two Years First Effective Non-Opioid Treatment in Two Decades Could be Available Within Two Years

A breakthrough drug containing theobromine, an ingredient naturally present in cocoa and chocolate, is entering the final stages of human clinical trials for the treatment of persistent cough, researchers announced today. The drug is being jointly developed by SEEK, a leading UK privately-owned drug-discovery group, and could be on the market within two years.
20 December 2010

New Data Suggest a Potential Role for AT9283 in Combination With Lenalidomide and With Docetaxel in the Treatment of Multiple Myeloma and Non-Hodgkin’s Lymphoma New Data Suggest a Potential Role for AT9283 in Combination With Lenalidomide and With Docetaxel in the Treatment of Multiple Myeloma and Non-Hodgkin’s Lymphoma

Astex Therapeutics, the UK-based biotechnology company developing targeted therapies for oncology and virology, today announced presentations of new data on its combinatorial oncogenic kinase inhibitor AT9283. The presentations will be made during the 52nd American Society of Hematology Meeting, 4-7th December in Orlando.
08 December 2010

Fostamatinib shows positive response in rheumatoid arthritis patients Fostamatinib shows positive response in rheumatoid arthritis patients

AstraZeneca’s new oral syk inhibitor, fostamatinib (R788), significantly improves outcomes of patients with rheumatoid arthritis who respond inadequately to methotrexate, according to phase II study data.
22 September 2010

Cancer Research UK and AstraZeneca to trial first-of-kind drug Cancer Research UK and AstraZeneca to trial first-of-kind drug

Cancer Research UK and Cancer Research Technology have reached an agreement with AstraZeneca to take compound AZD-3965, a first-of-its-kind experimental drug that could treat a range of cancers, into clinical trial.
13 September 2010

Study shows PRADAXA reduces stroke risk Study shows PRADAXA reduces stroke risk

Newly published sub-group analysis from the landmark RE-LY® study has shown dabigatran etexilate significantly reduces the risk of stroke compared to warfarin, irrespective of centre-based international normalized ratio control.
13 September 2010